90
Participants
Start Date
March 11, 2024
Primary Completion Date
February 28, 2027
Study Completion Date
February 28, 2027
Oral calcitriol with cinacalcet rescue
Participants will receive in-center oral calcitriol at a fixed dose of 0.5 mcg three times weekly at their dialysis treatment sessions regardless of their parathyroid hormone (PTH) concentrations over the 12-month trial period. Only if their serum PTH exceeds 800 pg/mL over 2 consecutive measurements will they be started on cinacalcet at 30 mg/d in order to protect against severe unremitting hyperparathyroidism.
IV activated vitamin D
Participants will continue to receive intravenously-administered activated vitamin D per the Northwest Kidney Center treatment protocol, dose-titrated to monthly to quarterly parathyroid hormone concentrations.
University of Washington, Seattle
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of Washington
OTHER